Mice lacking the serotonin Htr 2B receptor gene present an antipsychotic-sensitive schizophrenic-like phenotype

Neuropsychopharmacology

Volumn 40, Issue 12, 2015, Pages 2764-2773

  Pitychoutis, Pothitos M ^a,b   Belmer, Arnauld ^a   Moutkine, Imane ^a   Adrien, Joëlle ^c   Maroteaux, Luc ^a  

^a INSTITUT DU FER À MOULIN   (France)

^b UNIVERSITY OF DAYTON   (United States)

^c INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DIZOCILPINE; DOPAMINE; GLUTAMIC ACID; HALOPERIDOL; SEROTONIN 2B RECEPTOR; DIZOCILPINE MALEATE; NEUROLEPTIC AGENT;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; ENDOPHENOTYPE; LATENT INHIBITION; LEARNING; LOCOMOTION; MALE; MEMORY; MOUSE; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RECEPTOR GENE; SCHIZOPHRENIA; SELECTIVE ATTENTION; SENSORY GATING; SLEEP; SOCIAL INTERACTION; STARTLE REFLEX; ANIMAL; ASSOCIATION; COHORT ANALYSIS; CONDITIONING; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; FEAR; GENETICS; INHIBITION (PSYCHOLOGY); MOTOR ACTIVITY; RECOGNITION; SOCIAL BEHAVIOR; TRANSGENIC MOUSE; WAKEFULNESS;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; CONDITIONING (PSYCHOLOGY); CUES; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; FEAR; INHIBITION (PSYCHOLOGY); MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; RECEPTOR, SEROTONIN, 5-HT2B; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA; SENSORY GATING; SOCIAL BEHAVIOR; WAKEFULNESS;

EID: 84944351848     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.126     Document Type: Article

References (50)

1. Abbas AI, Hedlund PB, Huang X-P, Tran TB, Meltzer HY, Roth BL (2009). Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology 205: 119-128.
2. Arguello PA, Gogos JA (2006). Modeling madness in mice: one piece at a time. Neuron 52: 179-196.
3. Auclair AL, Cathala A, Sarrazin F, Depoortre R, Piazza PV, Newman-Tancredi A et al (2010). The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J Neurochem 114: 1323-1332.
4. Banas S, Doly S, Boutourlinsky K, Diaz S, Belmer A, Callebert J et al (2011). Deconstructing antiobesity compound action: requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects. Neuropsychopharmacology 36: 423-433.
5. Bevilacqua L, Doly S, Kaprio J, Yuan Q, Tikkanen R, Paunio T et al (2010). A population-specific HTR2B stop codon predisposes to severe impulsivity. Nature 468: 1061-1066.
6. Blundell J, Blaiss CA, Etherton MR, Espinosa F, Tabuchi K, Walz C et al (2010). Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. J Neurosci 30: 2115-2129.
7. Boutrel B, Franc B, Hen R, Hamon M, Adrien J (1999). Key role of 5-HT1B receptors in the regulation of paradoxical sleep as evidenced in 5-HT1B knock-out mice. J Neurosci 19: 3204-3212.
8. Cai WH, Blundell J, Han J, Greene RW, Powell CM (2006). Postreactivation glucocorticoids impair recall of established fear memory. J Neurosci 26: 9560-9566.
9. Carlini VP, Martini AC, Schioth HB, Ruiz RD, Fiol de Cuneo M, de Barioglio SR (2008). Decreased memory for novel object recognition in chronically food-restricted mice is reversed by acute ghrelin administration. Neuroscience 153: 929-934.
10. Diaz SL, Doly S, Narboux-Nme N, Fernandez S, Mazot P, Banas S et al (2012). 5-HT2B receptors are required for serotonin-selective antidepressant actions. Mol Psychiatry 17: 154-163.
11. Diaz SL, Maroteaux L (2011). Implication of 5-HT2B receptors in the serotonin syndrome. Neuropharmacology 61: 495-502.
12. Doly S, Bertran-Gonzalez J, Callebert J, Bruneau A, Banas SM, Belmer A et al (2009). Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice. PLoS One 4: e7952.
13. Doly S, Valjent E, Setola V, Callebert J, Herve D, Launay JM et al (2008). Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine- induced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci 28: 2933-2940.
14. Fineberg NA, Potenza MN, Chamberlain SR, Berlin HA, Menzies L, Bechara A et al (2010). Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology 35: 591-604.
15. Gleason KA, Birnbaum SG, Shukla A, Ghose S (2012). Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia. Transl Psychiatry 2: e199.
16. Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF et al (2008). Identification of a serotonin/ glutamate receptor complex implicated in psychosis. Nature 452: 93-97.
17. Gordon JA (2010). Testing the glutamate hypothesis of schizophrenia. Nat Neurosci 13: 2-4.
18. Gunduz-Bruce H (2009). The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev 60: 279-286.
19. Hervas A, Toma C, Romaris P, Ribases M, Salgado M, Bayes M et al (2014). The involvement of serotonin polymorphisms in autistic spectrum symptomatology. Psychiatr Genet 24: 158-163.
20. Hirvonen J, van Erp TG, Huttunen J, Aalto S, Nagren K, Huttunen M et al (2005). Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 62: 371-378.
21. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P et al (2009). Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66: 13-20.
22. Humby T, Wilkinson LS (2011). Assaying dissociable elements of behavioural inhibition and impulsivity: translational utility of animal models. Curr Opin Pharmacol 11: 534-539.
23. Kantor S, Jakus R, Balogh B, Benko A, Bagdy G (2004). Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT2B receptor by the subtype-selective antagonist SB-215505. Br J Pharmacol 142: 1332-1342.
24. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA (2008). Schizophrenia, just the facts: what we know in 2008 Part 3: neurobiology. Schizophr Res 106: 89-107.
25. Kiss B, Horvath A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G et al (2010). Cariprazine (RGH-188), a dopamine D (3) receptor-preferring, D(3)/D(2) dopamine receptor antagonistpartial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333: 328-340.
26. Kvajo M, McKellar H, Gogos JA (2012). Avoiding mouse traps in schizophrenia genetics: lessons and promises from current and emerging mouse models. Neuroscience 211: 136-164.
27. Launay JM, Schneider B, Loric S, Da Prada M, Kellermann O (2006). Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells. FASEB J 20: 1843-1854.
28. Lena C, Popa D, Grailhe R, Escourrou P, Changeux JP, Adrien J (2004). Beta2-containing nicotinic receptors contribute to the organization of sleep and regulate putative micro-arousals in mice. J Neurosci 24: 5711-5718.
29. Lubow RE, Moore AU (1959). Latent inhibition: the effect of nonreinforced pre-exposure to the conditional stimulus. J Comp Physiol Psychol 52: 415-419.
30. Lyon L, Saksida LM, Bussey TJ (2012). Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models. Psychopharmacology (Berl) 220: 647-672.
31. Meltzer HY (2013). Update on typical and atypical antipsychotic drugs. Annu Rev Med 64: 393-406.
32. Meltzer HY, Massey BW (2011). The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 11: 59-67.
33. Meyer U, Feldon J, Schedlowski M, Yee BK (2005). Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 29: 913-947.
34. Monti JM, Monti D (2004). Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med Rev 8: 133-148.
35. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B (2012). The economic cost of brain disorders in Europe. Eur J Neurol 19: 155-162.
36. Peca J, Feliciano C, Ting JT, Wang W, Wells MF, Venkatraman TN et al (2011). Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472: 437-442.
37. Pitychoutis PM, Pallis EG, Mikail HG, Papadopoulou-Daifoti Z (2011). Individual differences in novelty-seeking predict differential responses to chronic antidepressant treatment through sexand phenotype-dependent neurochemical signatures. Behav Brain Res 223: 154-168.
38. Popa D, Lena C, Fabre V, Prenat C, Gingrich J, Escourrou P et al (2005). Contribution of 5-HT2 receptor subtypes to sleepwakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors. J Neurosci 25: 11231-11238.
39. Powell CM, Schoch S, Monteggia L, Barrot M, Matos MF, Feldmann N et al (2004). The presynaptic active zone protein RIM1alpha is critical for normal learning and memory. Neuron 42: 143-153.
40. Powell SB, Zhou X, Geyer MA (2009). Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res 204: 282-294.
41. Pratt J, Winchester C, Dawson N, Morris B (2012). Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov 11: 560-579.
42. Seeman P, Kapur S (2000). Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci USA 97: 7673-7675.
43. Shahid M, Walker GB, Zorn SH, Wong EHF (2009). Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharm 23: 65-73.
44. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR et al (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28: 1400-1411.
45. Simpson EH, Kellendonk C, Kandel E (2010). A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65: 585-596.
46. Takahashi H, Higuchi M, Suhara T (2006). The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol Psychiatry 59: 919-928.
47. Terry AV Jr, Gearhart DA, Warner SE, Zhang G, Bartlett MG, Middlemore ML et al (2007). Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance. Neuroscience 146: 1316-1332.
48. Tobler I, Deboer T, Fischer M (1997). Sleep and sleep regulation in normal and prion protein-deficient mice. J Neurosci 17: 1869-1879.
49. Willi R, Weinmann O, Winter C, Klein J, Sohr R, Schnell L et al (2010). Constitutive genetic deletion of the growth regulator Nogo-A induces schizophrenia-related endophenotypes. J Neurosci 30: 556-567.
50. Yadav PN, Abbas AI, Farrell MS, Setola V, Sciaky N, Huang X-P et al (2011). The presynaptic component of the serotonergic system is required for clozapine's efficacy. Neuropsychopharmacology 36: 638-651.